These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 22108624)

  • 1. Factor VII light chain-targeted lidamycin targets tissue factor-overexpressing tumor cells for cancer therapy.
    Zhang Q; Liu XJ; Hu L; Liao DS; Zheng YB; Zhen YS; Song X
    Int J Mol Med; 2012 Mar; 29(3):409-15. PubMed ID: 22108624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factor VII light chain-targeted lidamycin shows intensified therapeutic efficacy for liver cancer.
    Zhang Q; Liu X; Xu S; Li C; Zhang Y; Yang J; Zheng J
    Cancer Biother Radiopharm; 2012 Aug; 27(6):384-91. PubMed ID: 22651685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A bispecific enediyne-energized fusion protein containing ligand-based and antibody-based oligopeptides against epidermal growth factor receptor and human epidermal growth factor receptor 2 shows potent antitumor activity.
    Guo XF; Zhu XF; Shang Y; Zhang SH; Zhen YS
    Clin Cancer Res; 2010 Apr; 16(7):2085-94. PubMed ID: 20332319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A tandem scFv-based fusion protein and its enediyne-energized analogue show intensified therapeutic efficacy against lung carcinoma xenograft in athymic mice.
    Zhong G; Zhang S; Li Y; Liu X; Gao R; Miao Q; Zhen Y
    Cancer Lett; 2010 Sep; 295(1):124-33. PubMed ID: 20303650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor efficacy of the scFv-based fusion protein and its enediyne-energized analogue directed against epidermal growth factor receptor.
    Sheng W; Shang Y; Miao Q; Li Y; Zhen Y
    Anticancer Drugs; 2012 Apr; 23(4):406-16. PubMed ID: 22205154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An EGFR/CD13 bispecific fusion protein and its enediyne-energized analog show potent antitumor activity.
    Sheng W; Shang Y; Li L; Zhen Y
    Anticancer Drugs; 2014 Jan; 25(1):82-91. PubMed ID: 24100279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor effects of an engineered and energized fusion protein consisting of an anti-CD20 scFv fragment and lidamycin.
    Fang H; Miao Q; Zhang S; Cheng X; Xiong D; Zhen Y
    Sci China Life Sci; 2011 Mar; 54(3):255-62. PubMed ID: 21416325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor activities of dFv-LDP-AE: An enediyne-energized fusion protein targeting tumor-associated antigen gelatinases.
    Zhong GS; Wu MN; Guo XF; Zhang SH; Miao QF; Zhen YS
    Oncol Rep; 2012 Oct; 28(4):1193-9. PubMed ID: 22797730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A bispecific fusion protein and a bifunctional enediyne-energized fusion protein consisting of TRAIL, EGFR peptide ligand, and apoprotein of lidamycin against EGFR and DR4/5 show potent antitumor activity.
    Zhu D; Wang X; Shang Y; Li Y; Jiang W; Li L; Chen SZ
    Anticancer Drugs; 2015 Jan; 26(1):64-73. PubMed ID: 25122444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation and antitumor effects of an engineered and energized fusion protein VL-LDP-AE composed of single-domain antibody and lidamycin.
    Miao Q; Shang B; Ouyang Z; Liu X; Zhen Y
    Sci China C Life Sci; 2007 Aug; 50(4):447-56. PubMed ID: 17653664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An NGR-integrated and enediyne-energized apoprotein shows CD13-targeting antitumor activity.
    Zheng YB; Shang BY; Li Y; Zhen YS
    Biomed Pharmacother; 2013 Mar; 67(2):164-71. PubMed ID: 23206754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A bispecific enediyne-energized fusion protein targeting both epidermal growth factor receptor and insulin-like growth factor 1 receptor showing enhanced antitumor efficacy against non-small cell lung cancer.
    Guo XF; Zhu XF; Cao HY; Zhong GS; Li L; Deng BG; Chen P; Wang PZ; Miao QF; Zhen YS
    Oncotarget; 2017 Apr; 8(16):27286-27299. PubMed ID: 28460483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tissue factor-targeted lidamycin inhibits growth and metastasis of colon carcinoma.
    Zhang Q; Liu X; Li C; Liao D; Ouyang Z; Zheng J; Song X
    Oncol Lett; 2013 Sep; 6(3):801-806. PubMed ID: 24137414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR-targeting, β-defensin-tailored fusion protein exhibits high therapeutic efficacy against EGFR-expressed human carcinoma via mitochondria-mediated apoptosis.
    Liu WJ; Liu XJ; Xu J; Li L; Li Y; Zhang SH; Wang JL; Miao QF; Zhen YS
    Acta Pharmacol Sin; 2018 Nov; 39(11):1777-1786. PubMed ID: 30013033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetically engineered endostatin-lidamycin fusion proteins effectively inhibit tumor growth and metastasis.
    Jiang WG; Lu XA; Shang BY; Fu Y; Zhang SH; Zhou D; Li L; Li Y; Luo Y; Zhen YS
    BMC Cancer; 2013 Oct; 13():479. PubMed ID: 24128285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A cell penetrating peptide-integrated and enediyne-energized fusion protein shows potent antitumor activity.
    Ru Q; Shang BY; Miao QF; Li L; Wu SY; Gao RJ; Zhen YS
    Eur J Pharm Sci; 2012 Nov; 47(4):781-9. PubMed ID: 22982402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Construction of energized fusion protein consisting of epidermal growth factor receptor oligopeptide ligand and lidamycin and its antitumor activity].
    Guo XF; Zhong GS; Miao QF; Zhen YS
    Ai Zheng; 2009 Jun; 28(6):561-8. PubMed ID: 19635191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An EGFR/HER2-Bispecific and enediyne-energized fusion protein shows high efficacy against esophageal cancer.
    Guo XF; Zhu XF; Yang WC; Zhang SH; Zhen YS
    PLoS One; 2014; 9(3):e92986. PubMed ID: 24664246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Binding capability of the enediyne-associated apoprotein to human tumors and constitution of a ligand oligopeptide-integrated protein.
    Cai L; Chen H; Miao Q; Wu S; Shang Y; Zhen Y
    J Biotechnol; 2009 Oct; 144(2):142-50. PubMed ID: 19737585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tuftsin-based, EGFR-targeting fusion protein and its enediyne-energized analog show high antitumor efficacy associated with CD47 down-regulation.
    Liu WJ; Liu XJ; Li L; Li Y; Zhang SH; Zhen YS
    Cancer Immunol Immunother; 2014 Dec; 63(12):1261-72. PubMed ID: 25164878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.